The Fellow on Call: The Heme/Onc Podcast

This week, we are so excited to share the first of our Career Development Series episodes, developed in partnership with The American Society of Hematology , The ASH Trainee Council, and Hematopoiesis!
For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this happen!
This time, we welcome two amazing guests, Dr. Hetty Carraway, Director of the Leukemia Program and the Vice Chair of Strategy and Enterprise Development at the Taussig Cancer Institute at The Cleveland Clinic, and Dr. Alfred Lee, Chief of Classical Hematology at Yale School of Medicine, for our inaugural episode where we discuss the importance of mentorship and ask them all the questions most of us have always wondered but are too afraid to ask our mentors. A MUST listen for all trainees!
** This episode is created in partnership with The American Society of Hematology (hematology.org), The ASH Trainee Council (https://www.hematology.org/education/trainees/fellows/trainee-council), and Hematopoeisis (https://www.hematology.org/education/trainees/fellows/hematopoiesis)
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube

This week, we begin our discussion about treatment of multiple myeloma, focusing on the first-line setting. Once again, a lot has changed in this space over the last few years, most notably the standards of care (now quadruplet regimens instead of triplet regimens!). We break down the data and how to help you practically approach your treatment planning for your patient with newly diagnosed multiple myeloma.
Content:
- What are the phases of treatment for multiple myeloma
- What are our current treatment standards of care?
- How do we select the agents to include in our first-line regimens?
- How do we stratify patients into quadruplet vs. triplet eligible? What about transplant eligible vs. ineligible?
** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube

This week, we introduce a new episode for our myeloma series, this time focusing on risk stratification and response criteria. The initial workup and surveillance labs are expansive, but all of the studies we do have a purpose.
Many present-day studies also use “minimal residual disease” (MRD) testing. What does this mean? How do we use this?
We go through all of this and more in this incredibly high yield episode.
Content:
- How do we risk stratify patients with newly diagnosed MM?
- What are the criteria used to risk stratify? Why does this matter?
- How do we define response to treatment? Progression?
- What is the role of "minimal residual disease" in myeloma?
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube

We bring back our prior pharmacology discussion because it’s so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!
Content:
- What are common drugs we use in "triplet regimens"? "quadruple therapy"?
- What considerations must we take into account when prescribing commonly used medications in myeloma?
- How should we counsel our patients?
- What about supportive care?
- How and when do we make dose adjustments?
- This episode is SO eye-opening about the "behind the scenes" of myeloma care that physicians do not see
Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast

We bring back our prior pharmacology discussion because it’s so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!
Content:
- What are common drugs we use in "triplet regimens"? "quadruple therapy"?
- What considerations must we take into account when prescribing commonly used medications in myeloma?
- How should we counsel our patients?
- What about supportive care?
- How and when do we make dose adjustments?
- This episode is SO eye-opening about the "behind the scenes" of myeloma care that physicians do not see
Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast